An employee of the Cebu City Government plans to file charges against former officials of the Department of Health (DOH) and a private medicine provider after admitting responsibility for the effects of Dengvaxia, the vaccine against dengue.
In an interview with SunStar Cebu, the employee, who is also a lawyer, asks not to be named because he is still studying the charges.
"The company has already admitted its responsibility, so there is no need to prove its negligence, the problem there is to rectify its error and compensate the affected parties," he said.
Dengvaxia, also known as CYD-TDV, is the first authorized dengue vaccine developed by Sanofi Pasteur.
He also asked those who used the vaccine to join him in the complaint. Some have already expressed interest in filing a clbad action.
The employee said that he, his two minor children and two others received the vaccine to supposedly protect them from the deadly disease. His 14-year-old son had contracted dengue in 2012.
Last Friday, the DOH suspended its $ 3 billion dengue vaccination program after a new badysis revealed that Dengvaxia has a higher risk of severe dengue. those who had not previously been infected with the virus.
When he found out, the employee said he was disappointed and felt betrayed.
The Secretary of Health, Francisco Duque, at a press conference, asked the public not to be terrified, saying that they are intensifying the monitoring and surveillance of children, aged nine or older, who received the vaccine.
According to DOH records, a total of 733,713 children from Central Luzon, Calabarzon and National Capital Region received Dengvaxia from last month.
Dengvaxia is administered to people aged 9 to 45 years as a series of three doses at a time of 0/6/12 months.
According to the study published in the Journal Science and quoted in an article published on statnews.com, the vaccine should only be used in places with a lot of dengue activity and where most of the children who receive it have already had at least one episode of the disease.
"That's because the data from the studies used to approve the vaccine … showed a higher rate of dengue hospitalizations three years after vaccination in young children who received the vaccine compared to children who were not vaccinated, "the article reads.
Children who had not been exposed to dengue infections when they were vaccinated have an increased risk of contracting the virus, the study added.